Literature DB >> 17284123

The art and science of switching antipsychotic medications, part 2.

Peter J Weiden1, Alexander L Miller, Tim J Lambert, Peter F Buckley.   

Abstract

In the presentation "Switching and Metabolic Syndrome," Weiden summarizes reasons to switch antipsychotics, highlighting weight gain and other metabolic adverse events as recent treatment targets. In "Texas Medication Algorithm Project (TMAP)," Miller reviews the TMAP study design, discusses results related to the algorithm versus treatment as usual, and concludes with the implications of the study. Lambert's presentation, "Dosing and Titration Strategies to Optimize Patient Outcome When Switching Antipsychotic Therapy," reviews the decision-making process when switching patients' medication, addresses dosing and titration strategies to effectively transition between medications, and examines other factors to consider when switching pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284123     DOI: 10.4088/jcp.0107e02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study.

Authors:  Rayees Ahmad Wani; Mansoor Ahmad Dar; Rajesh Kumar Chandel; Yasir Hassan Rather; Inaamul Haq; Arshad Hussain; Altaf Ahmad Malla
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-13       Impact factor: 2.570

2.  Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study.

Authors:  Yongmin Kim; Sheng-Min Wang; Kyung-Phil Kwak; Ho-Kyoung Yoon; Chi-Un Pae; Jung-Jin Kim; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

3.  Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study.

Authors:  Young Sup Woo; Bo-Hyun Yoon; Bong-Hee Jeon; Jeong Seok Seo; Beomwoo Nam; Sang-Yeol Lee; Young-Myo Jae; Sae-Heon Jang; Hun Jeong Eun; Seung-Hee Won; Kwanghun Lee; Jonghun Lee; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.